Correspondence 0001193125-24-235258 from Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc
Date: Oct. 9, 2024 · CIK: 0001541157 · Accession: 0001193125-24-235258
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282127
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Joshua Gorsky Re: Akari Therapeutics, Plc Registration Statement on Form S-4 File No. 333-282127
Dear Mr. Gorsky:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Akari Therapeutics, Plc hereby requests that the effective date of the above-referenced Registration Statement be accelerated to, and the Registration Statement become effective on, October 11, 2024, at 4:45 P.M. Eastern Time, or as soon thereafter as practicable.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Jennifer L. Porter at (445) 207-7806. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Jennifer L. Porter, by email at JPorter@goodwinlaw.com.
[Signature page follows]
Sincerely yours,
Akari Therapeutics, Plc
Show Raw Text
CORRESP 1 filename1.htm CORRESP October 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Akari Therapeutics, Plc Registration Statement on Form S-4 File No. 333-282127 Dear Mr. Gorsky: In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Akari Therapeutics, Plc hereby requests that the effective date of the above-referenced Registration Statement be accelerated to, and the Registration Statement become effective on, October 11, 2024, at 4:45 P.M. Eastern Time, or as soon thereafter as practicable. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Jennifer L. Porter at (445) 207-7806. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Jennifer L. Porter, by email at JPorter@goodwinlaw.com. [Signature page follows] Sincerely yours, Akari Therapeutics, Plc By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President, Chief Executive Officer cc: Rachael M. Bushey, Goodwin Procter LLP Jennifer L. Porter, Goodwin Procter LLP Laura Umbrecht Gulick, Goodwin Procter LLP [Signature Page to Acceleration Request]